A Study of a Renal Autologous Cell Therapy (REACT) in Patients With Chronic Kidney Disease (CKD) From Congenital Anomalies of the Kidney and Urinary Tract (CAKUT).
Part of paid clinical trials in Atlanta, Georgia.
- Sponsor
- Prokidney
- Study ID
- NCT04115345
- Phase
- PHASE1
- Status
- Completed
Conditions
- Chronic Kidney Disease
- Congenital Anomalies of Kidney and Urinary Tract
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- Renal Autologous Cell Therapy (REACT) — BIOLOGICALAutologous selected renal cells (SRC)
Study Details
A phase 1, open-label safety, tolerability and early efficacy study of a Renal Autologous Cell Therapy (REACT) in patients with Chronic Kidney Disease from Congenital Anomalies of the Kidney and Urinary Tract (CAKUT) (REGEN-004)
Key Dates
- First listed
- Oct 4, 2019
- Start date
- Aug 13, 2019
- Status verified
- Feb 2023
- Primary completion
- Jan 31, 2023
- Completion
- Jan 31, 2023
Study Design
- Enrollment
- 6 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Renal Autologous Cell Therapy (REACT)The volume of REACT to be administered will be determined by pre-procedure MRI volumetric 3D evaluation or ellipsoid formula. The participant will receive a second injection 6 months after the first injection into the same kidney.
Primary Outcome Measure
Assess change in eGFR and observe incidence of renal-specific procedure and/or product related adverse events (AEs) through 18 months following two Renal Autologous Cell Therapy (REACT) injections [Safety]. [ Time Frame: 18 months following last REACT injection ]
Locations (5)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Emory University Hospital | Atlanta | Georgia | 30322 | - |
| Boise Kidney & Hypertension Institute | Meridian | Idaho | 83642 | - |
| Hackensack Meridian Jersey Shore University Medical Center | Neptune City | New Jersey | 07753 | - |
| Mt. Sinai Hospital | New York | New York | 45246 | - |
| University of North Carolina- Chapel Hill | Chapel Hill | North Carolina | 27599 | - |
Find similar trials in Atlanta, GA
By condition
By specialty
Related Studies
- Clinical Phenotyping Resource and Biobank Core of the Michigan O'Brien Renal CenterRecruiting · University of Michigan · Ann Arbor, Michigan
- Sympatholysis in Chronic Kidney DiseasePHASE1 · Recruiting · Emory University · Decatur, Georgia
- A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on HemodialysisPHASE3 · Recruiting · Amgen · Los Angeles, California
- A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and ProteinuriaPHASE3 · Recruiting · Bayer · Phoenix, Arizona